Showing 4181-4190 of 7373 results for "".
- Ellzey Coding Solutions Introduces ICD-10 for Dermatology Manualhttps://practicaldermatology.com/news/20131010-ellzey_coding_solutions_introduces_icd-10_for_dermatology_manual/2459440/Ellzey Coding Solutions, Inc., recently released an ICD-10 coding manual specifically for dermatologists. The 2014 ICD-10 for Dermatology program is a tool that can be used to prepare dermatologists and staff with what they need to know about the ICD-10-CM diagnosis coding syste
- Medicis Announces Winners of First Annual I Acanya Succeed Scholarship Programhttps://practicaldermatology.com/news/20131007-medicis_announces_winners_of_first_annual_i_acanya_succeed_scholarship_program/2459442/Medics, a division of Valeant Pharmaceuticals North America LLC, recently announced the winners of its first I Acanya Succeed scholarship program, an education-based initiative that provides scholarships to college students who h
- MELA Sciences Appoints Dr. Darrell Rigel as Chief Medical Advisor to Its Board of Directorshttps://practicaldermatology.com/news/20131001-mela_sciences_appoints_dr_darrell_rigel_as_chief_medical_advisor_to_its_board_of_directors/2459445/MELA Sciences, Inc., announced that Darrell S. Rigel, MD, MS, Clinical Professor of Dermatology at New York University, Langone Medical Center, has been appointed Chief Medical Advisor to the Company's Board of Directors. Dr. Rigel is a Clinical Profes
- TSLMS Announces New Name for its Meeting: Symposium for Cosmetic Advances and Laser Educationhttps://practicaldermatology.com/news/20131001-tslms_announces_new_name_for_its_meeting_symposium_for_cosmetic_advances_and_laser_education/2459447/The Tennessee Society for Laser Medicine & Surgery (TSLMS) announced that its 9th annual meeting Feb. 22-Mar. 2, 2014. The TSLMS introduced
- Patient Savings Program Available for Mylan's Doxycycline Hyclatehttps://practicaldermatology.com/news/20130925-patient_savings_program_available_for_mylans_doxycycline_hyclate/2459450/Patients who are prescribed Mylan's bioequivalent alternative to Doryx (doxycycline hyclate delayed-release tablets) USP for severe acne may be eligible for an instant savings program. Patients who take their prescriptions to participating pharmacies will receive an automatic co-pay reduction at the
- KYTHERA Biopharmaceuticals, Inc. Names F. Michael Ball to Boardhttps://practicaldermatology.com/news/20130925-kythera_biopharmaceuticals_inc_names_f_michael_ball_to_board/2459451/KYTHERA Biopharmaceuticals, Inc. has named F. Michael (Mike) Ball, Chief Executive Officer (CEO) of Hospira, Inc. to its Board of Directors. Mr. Ball brings more than 25 years of healthcare experience to KYTHERA. Mr. Ball was appointe
- Elevator Pitch Sessions Launching from The Medical Entrepreneurhttps://practicaldermatology.com/news/20130924-elevator_pitch_sessions_launching__from_the_medical_entrepreneur/2459454/The Medical Entrepreneur Symposium is introducing a one day event on Saturday December 7 in Delray Beach. The “Elevator Pitch Sessions” will be geared towards helping physicians learn how to fund their next venture. "We are excite
- ResurFX for M22 Platform from Lumenis Receives FDA Clearancehttps://practicaldermatology.com/news/20130917-resurfx_for_m22_platform_from_lumenis_receives_fda_clearance/2459459/The FDA recently granted 510(k) clearance for ResurFX, a new fractional non-ablative laser module from Lumenis. ResurFX is the latest application module for the company's M22 platform, expanding its capabilities to perform true fractional non-ablative skin resurfacing.
- GSK Receives FDA Priority Review for Dabrafenib/Trametinib Combination in Metastatic Melanomahttps://practicaldermatology.com/news/20130916-gsk_receives_priority_review_from_fda_for_dabrafenibtrametinib_combination_in_metastatic_melanoma/2459460/The FDA has granted priority review designation to GlaxoSmithKline's supplemental New Drug Applications (sNDAs) for combined use of Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or
- Data for PV-10 in Melanoma to be Presented at European Cancer Congresshttps://practicaldermatology.com/news/20130913-data_for_pv-10_in_melanoma_to_be_presented_at_european_cancer_congress/2459461/Analysis of data from Provectus Pharmaceuticals, Inc.'s completed Phase 2 study of intralesional PV-10 in metastatic melanoma will be presented at the upcoming European Cancer Congress (ECCO 17- ESMO-38 - ESTRO 32), taking place September 27 through